Compound isosorbide mononitrate aspirin sustained-release capsule preparation and preparation method

Abstract

The invention discloses a compound isosorbide mononitrate aspirin sustained-release capsule preparation. The compound isosorbide mononitrate aspirin sustained-release capsule preparation is characterized by comprising an isosorbide mononitrate sustained-release capsule preparation and an aspirin enteric-coated preparation, wherein the isosorbide mononitrate sustained-release capsule preparation contains 40-80 parts by weight of isosorbide mononitrate and comprises an immediate-release pellet with 30 percent of isosorbide mononitrate and a sustained-release pellet with 70 percent of isosorbide mononitrate, and the aspirin enteric-coated preparation contains 50-90 parts by weight of aspirin. The invention also provides a preparation method of the compound capsule preparation. With the adoption of the compound isosorbide mononitrate aspirin sustained-release capsule preparation, the curative effects are better improved, the adverse reaction due to stimulation from the aspirin to a gastric mucosa is better reduced, and meanwhile, the isosorbide mononitrate can also satisfy the requirement of stable release in a stomach.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a compound isosorbide mononitrate aspirin sustained-release capsule preparation and a preparation method thereof. Background technique [0002] Isosorbide mononitrate, whose chemical name is 1,4:3,6-dianhydro-D-sorbitol-5-mononitrate, is the main biologically active metabolite of isosorbide dinitrate, and is used for the treatment of angina pectoris and myocardial infarction. One of the most commonly used drugs, the drug can reduce myocardial oxygen consumption by dilating peripheral blood vessels, especially increasing venous blood volume, reducing blood return to the heart, reducing cardiac preload and postload; The blood flow supply in the blood area makes the myocardial blood supply and oxygen supply tend to balance and play an anti-angina role. Because of its fast onset, strong effect and definite curative effect, it is widely used clinically. Oral ordinary table...

AI Technical Summary

Problems solved by technology

The initial drug release of isosorbide mononitrate slow-release layer is slow, the blood concentration is low, and the drug release is easily affected by the speed of gastrointestinal peristalsis, the reproducibility of drug release is poor, and individual differences are large; the aspirin layer It is an immediate-release layer, which often produces gastrointestinal reactions such as nausea, vomiting, upper abdominal discomfort or pain during the prevention and treatment of thrombotic diseases, and long-term use will cause damage to the gastric mucosa

Images